IRLAB Reports Positive Results from the Second Part of a Phase I Study with IRL757
"We are very pleased that IRL757 is well absorbed and provides good exposure in the body while demonstrating excellent tolerability and a favorable safety profile. These results give us a strong foundation for the continued clinical development of the drug candidate, which has the potential to treat and counteract apathy in millions of patients with neurodegenerative diseases," says Dr. Joakim Tedroff, MD, Chief Medical Officer at IRLAB.
The Phase I study has been funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) through a grant of just over SEK 20 million. MJFF is the world's largest non-profit funder of Parkinson's disease research, and the organization's support for IRL757 means a strong external validation of the project's goals and potential.
Based on the positive results from the completed Phase I studies, a clinical Phase Ib study in Parkinson's disease and apathy has been initiated in cooperation with The McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies. The first patients are expected to be enrolled in the study in the second half of 2025. IRLAB and MSRD formed a collaboration in May 2024 to advance IRL757 through proof-of-concept trials as a potential treatment of apathy.
Apathy is characterized by indifference, resignation and a lack of response to what is happening in the outside world. The condition often leads to significant disability and caregiver distress, affecting a substantial proportion of people living with Parkinson's, Alzheimer's and other diseases related to the central nervous system. Currently, there are no drugs on the market to treat apathy. IRLAB's drug candidate IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This effect is believed to be associated with the drug candidate's unique ability to counteract disturbances in central nervous system nerve signaling proposed to underly apathy in several neurological conditions.
Om Fas I-studienThe Phase I study consists of two parts and aims to document the safety, tolerability and pharmacokinetic properties of IRL757 in healthy subjects. In the first part of the study, single ascending doses of the drug candidate are administered (SAD) and in the second part, multiple ascending doses are given (MAD). In addition, the possible influence of concomitant food intake will be documented.
For more information
Kristina Torfgård, CEOPhone: +46 730 60 70 99E-mail: kristina.torfgard@irlab.se
About IRL757
The drug candidate IRL757 is being developed as a treatment for apathy in Parkinson's disease and other neurological conditions. Apathy, a widespread and debilitating issue, affects over 20 million people in the U.S. and Europe alone without a currently available treatment. The prevalence is high, occurring in 1.1-4 million people (20-70 percent) being treated with Parkinson's in the eight major markets (China, EU5, Japan, and the US), and in 4.9-6.7 million people (43-59 percent) being treated for Alzheimer's disease in the ten major markets (Canada, China, EU5, Japan, South Korea, and the US). IRL757 has the potential to become the first treatment for apathy. The efficacy of IRL757 is thought to be linked to its unique ability to reverse disruption in cortical to sub-cortical nerve signalling, a key factor believed to contribute to apathy in neurological disorders.
About IRLAB
IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .
Attachments
IRLAB reports positive results from the second part of a Phase I study with IRL757
SOURCE: IRLAB Therapeutics
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
9 hours ago
- UPI
FDA approves ketamine product for surgical pain management
The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management. Ketamine is the only psychedelic or psychedelic-adjacent drug on the World Health Organization Essential Medicines List, with its global market projected to grow from $750 million to $3.42 billion by 2034. PharmaTher, which developed KETARx, believes there is a promising outlook for the ketamine market and that the FDA approval provides a strong foundation for expanding the development of ketamine across diverse therapeutic areas. These areas include depression, neurological disorders (Parkinson disease, amyotrophic lateral sclerosis), and rare or chronic pain conditions. "Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth," Fabio Chianelli, founder and CEO of PharmaTher, said in a statement. "We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders." Approval of KETARx was granted to PharmaTher. More Information Copyright © 2025 HealthDay. All rights reserved.
Business Upturn
9 hours ago
- Business Upturn
Terra Balcanica Intersects Gold Mineralization Over 72 m and Starts Drill Program At Brezani Target in Bosnia
Vancouver, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) — Terra Balcanica Resources Corp. ('Terra' or the 'Company') (CSE:TERA; FRA: UB1) is pleased to announce an expansion of the surface gold skarn system at Brezani and the start of the Phase III drill program at its Viogor-Zanik project, Bosnia and Herzegovina. Highlights The Brezani drillhole BRE23001 located 125 m SSW of the maiden Brezani drillhole intercepted 0.27 g/t Au over 72.3 m including 0.62 g/t Au over 7.5 m. Additionally, two antimony veined zones, 1.5 and 0.5 m wide were intersected, respectively (Figure 2); The drillhole BRE23002 located 145 m northwest of BRE23001 intercepted 1.51 Zn% over 6 m including 0.54% Sb over 1.65 m as well as 0.6 g/t Au over 2.85 m; The drillhole BRE23003 located 77 m southeast of the maiden Brezani drillhole encountered 0.19% Sb over 2.0 m as well as 0.6 g/t Au over 2.85 m; The drillhole BRE23004 located 92 m NNW of the maiden Brezani drillhole intercepted 0.62 g/t Au over 11.8 m including 1.03 g/t Au over 6.65 m; Exploration upside: Au-bearing, retrograde, chlorite overprinted skarn at Brezani has been now confirmed over 200 m in the N-S direction as it overlies the SE extent of the 1.2 km, NE-shallowing conductor interpreted to be Sb-Ag-Zn mineralized. The maiden Brezani drillhole BREDD002 intercepted 0.61 g/t AuEq over 88.0 m from surface (see Company news release from January 24th, 2023); Terra Balcanica's CEO, Dr. Aleksandar (Alex) Miskovic, commented: 'We are pleased to have expanded the gold footprint at Brezani. The Au bearing metasomatized hornfels intercepted from surface at BREDD002 three years ago were not just a one-off as the follow up drilling clearly suggests a skarn with the gold mineralization over 200 m laterally. Being close to the surface, this is a considerable value add at Brezani given the NE-shallowing, 20 m wide, fault hosted silver antimony horizon which is the real focus of the current Phase III drill program.' Brezani is located 8.4 km south of the Mineco Ltd. Sase Mine which produces approximately 330 kt of lead-zinc-silver-gold concentrate per year (Figure 1). The target hosts components of a large magmatic-hydrothermal system discovered by airobrne TEM-magnetic and geochemical surveys. The BRE23001 through 23004 diamond drill holes are located within the Au-in-soil anomaly and were intended to assess lithological variability and grade of the Au skarn along strike. Additionally, the drillholes tested the resistive volume above an abrupt change into a central magnetic low shell within the general >95th percentile magnetic high anomaly to verify the lateral extent of 0.61 g/t Au Eq. In the central BREDD002 (Figure 3). Drill Results Drillhole From (m) To (m) Length (m) Au (g/t) Ag (g/t) Sb (%) Zn (%) BRE23001 22.0 94.3 72.3 0.27 Including 32.0 39.5 7.5 0.62 Including 47.0 48.5 1.5 0.27 Including 77.3 77.8 0.5 0.53 BRE23002 98.05 104.1 6.0 17.6 1.51 Including 98.05 99.7 1.65 0.54 BRE23002 104.65 107.5 2.85 0.60 BRE23002 110.5 111.4 0.9 1.06 BRE23003 52.7 54.7 2.0 0.19 BRE23004 9.8 21.6 11.8 0.62 Including 11.7 18.3 6.65 1.03 BRE23004 38.7 51.9 13.2 0.19 BRE23004 102.0 103.5 1.45 0.39 Table 1. Assay results of key mineralized intervals for diamond drillholes BRE23001 through BREDD004. Interval lengths reported are drilled lengths and not true widths. Please click to view image Figure 1. The Bosnian Viogor-Zanik project with the Brezani skarn system to SE of the Sase mine. Please click to view image Figure 2. Satelite plain view of the four drill holes at Brezani correlateting to the Au surface hail from soil geochemisry. Hole ID Easting Northing Elevation Dip Azimuth Depth (m) Recovery (%) BRE23001 368453 4879916 845.87 -80 336 120.8 94.16 BRE23002 368358 4880043 852.74 -80 336 156.7 98.6 BRE23003 368504 4879974 868.05 -80 336 123.2 97.16 BRE23004 368442 4880119 902.40 -80 336 145.2 97.16 Table 2. Collar location and core recoveries for diamond drillholes BREDD001 and BREDD002 (UTM; WGS84). The BRE 23001 drillhole was initially characterized by mudstone with patchy calc-silicate alteration and disseminated and vein-hosted pyrite-pyrrhotite followed by calc-silicate hornfels with pyroxene veining and disseminated and quartz veinlet hosted chalcopyrite, pyrite and pyrrhotite (Figure 4). Medium grained garnet dominant exoskarn mineralogy is noted adjacent to chlorite-sericite altered diorite intrusives that have been altered to endoskarn with garnet and pyroxene. A gradient from garnet to pyroxene skarn can be observed in BRE23001 with movement away from the intrusive contact. Epithermal quartz-carbonate veining with arsenopyrite, and stibnite was observed as well. There was notably more intrusive within the shallow part of BRE23001 than BREDD002. Quartz veins are crosscut by later pyrite and then carbonate-sulphide veins which create a strong chlorite vein selvage, commonly with pyrrhotite. Please click to view image Figure 3. Conductivity-magnetic profile of the Brezani target looking NE. The four drill holes tested the resistive volume above an abrupt change into a central magnetic low shell (tirquoise blue) within the general >95th percentile magnetic high anomaly to verify the lateral extent of 0.61 g/t Au Eq. over 88 m from surface reported in the 674 m deep, central BREDD002. The BRE23004 intersected 8 meters of exo-skarn/calc-silicate (9.5m – 19.5m) with small intervals of intrusive adding up to around 2 meters. The altered rock may not strictly be a skarn as the grain size is not coarse. The mineral banding is very well developed and is larger grained on the whole that our classic calc-silicate. The banding appears to follow relict bedding and tectonic folding. The skarn mineralogy contains: pyroxene-garnet-wollastonite-calcite-actinolite-chlorite-epidote. There appears to be zonation with the upper part containing more light brown garnet bands and the lower part more dominant in blue pyroxene. An example of a similarly altered, blue pyroxene skarn interval returned up to 2.7g/t gold in BREDD002 from 37m to 38m. The intrusive appears to be sillicified possibly overprinting potassic with some sections altered to endoskarn. From 19.5m to 29m is exoskarn/calc-silicate dominant with small intervals of porphyry with some intervals altered to exoskarn. Banding within the skarn is nicely well developed and similar to previous intervals. Please click to view image Please click to view image Figure 4. left) Garnet skarn in contact with chlorite-sericite altered diorite intrusion. Veinlets of pyrrhotite-sphalerite are observed adjacent to the contact. The skarn is retrograde (chlorite-epidote) altered; right) Phyllic altered, plagioclase phyric diorite with quartz-molybdenite veining and crosscutting calcite-arsenopyrite-sphalerite veinlets. Phase III Drilling The 2025 drill program is a folow up onto the discovery made by the drill hole BREDD002 which intercepted ca. 20 m of intermediate sulfidation, base metal-rich, fault-breccia hosted Ag-Sb-Zn mineralization grading upwards of 436 g/t Ag Eq. which was previously detected via the 2021 heliborne TEM survey. The EM study revealed a 1.2 km long conductor shallowing towards northeast and eventually surfacing at the topographic high of the Brezani locality. The mineralogical textures form the initial intercept pierced through the ore zone suggest a stratigraphic level that is apparently below the so-called 'boiling zone' thus offering potential upside should one be intercepted updip during the current drill program. The lateral extent of the 17 degree dipping conductor interpreted as the Sb-Ag-Zn mineralization is 1.2 km in length, up to 600 m in width and 20 m thick as observed in BREDD002 offering a massive potential for a large tonnage ore body which is the goal of this year's campaign. The company's field team expressly built six drill pads on a challenging and steep terrane and the drilling has sommenced in earnest last Friday (Figure 5). Terra expects to comlete the first diamond drill hole by the end of Augist, 2025 with the laboratory assays in hand by mid to late September, 2025. A total of 2,100 m of drilling is planned with a possibility of increasing the program should intercepts justify further testing. Please click to view image Figure 5. Drill pad BRE23005 with the rig oriented at 345 azimuth and inclined at 70° to surface testing the deep conductor interpreted to be the previously intercepted Sb-Ag-Zn mineralization. QA/QC Half core (PQ3 and HQ3) samples were delivered to ALS Bor, Serbia for sample preparation and subsequent wet chemical analysis at the Loughrea laboratory in Ireland, an ISO/IEC 17025:2017 certified test facility. Sample preparation PREP-31BY method involved crushing the core to 70% less than 2 mm, rotary split 1.0 kg and pulverizing the split to greater than 85% passing 75 microns. Silver and base metals were analysed by ICP MS after a four-acid digest (ME-MS61). Gold was assayed by 30g fire assay with ICP AES finish (Au-ICP21). Over limit samples for base metals were re-analysed by the four-acid digest ICP-AES analyses termed ME-OG62. Control samples comprising the certified reference material CDN-ME-1501 (Canadian Resource Labs Ltd.), quarter core field duplicates and blanks were inserted at a rate of 5% and investigated as part of the Company's quality assurance and quality control program. Qualified Person Dr. Aleksandar Mišković, is the Company's designated Qualified Person for this news release within the meaning of National Instrument 43-101 Standards of Disclosure of Mineral Projects ('NI 43-101'). Dr. Mišković has reviewed and validated the information contained in this news release as factual and accurate. About the Company Terra Balcanica is a polymetallic and energy metals exploration company targeting large-scale mineral systems in the Balkans of southeastern Europe and norther Saskatchewan, Canada. The Company has 90% interest in the Viogor-Zanik Project in eastern Bosnia and Herzegovina. The Canadian assets comprise a 100% optioned portfolio of uranium-prospective licences at the outskirts of the world-renowned Athabasca basin: Charlot-Neely Lake, Fontaine Lake, Snowbird, and South Pendleton. The Company emphasizes responsible engagement with local communities and stakeholders. It is committed to proactively implementing Good International Industry Practice (GIIP) and sustainable health, safety, and environmental management. ON BEHALF OF THE BOARD OF DIRECTORS Terra Balcanica Resources Corp. Aleksandar Mišković President and CEO For further information, please contact Aleksandar Mišković at [email protected] , or visit our website at . Cautionary Statement This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively 'forward-looking statements'). The use of any of the words 'will', 'intends' and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
a day ago
- Yahoo
Repurchase of Truecaller B shares in week 33, 2025
STOCKHOLM, Aug. 18, 2025 /PRNewswire/ -- During 11 August 2025 and 15 August 2025 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 200,000 own B shares (ISIN: SE0016787071), corresponding to 0.06% of outstanding capital, as part of the share buyback programme initiated by the board of directors. Since the start of the program Truecaller has bought back 925,000 shares, corresponding to 0.26% of outstanding capital The share buybacks form part of the share buyback programme announced by Truecaller on 30 May 2025. The share buyback programme will run between 30 May up until the 2026 AGM which will be held in May 2026, and is carried out in accordance "Emittentregelverket". On the Annual General Meeting 2025 the Board was authorized to buy back B-shares up until the Annual General Meeting in 2026. The new authorization means that buybacks may be made so that the company's shareholding does not exceed ten (10) percent of the total number of shares in the company outstanding as of the date of the annual general meeting. Date: Aggregated dailyvolume (number ofshares): Weighted average shareprice per day (SEK): Total daily transactionvalue (SEK): 11 August 2025 30 000 47,05 1 411 374 12 August 2025 60 000 45,97 2 757 911 13 August 2025 50 000 45,99 2 299 395 14 August 2025 30 000 46,48 1 394 328 15 August 2025 30 000 47,58 1 427 476 Total accumulated overweek 33/2025 200 000 46.45 9 290 484 Total accumulatedduring the buybackprogram 925 000 53.66 49 633 169 All acquisitions have been carried out on Nasdaq Stockholm by Carnegie on behalf of Truecaller. Following the above acquisitions. Truecaller's holding of own shares amounts to 4,870,332 B shares and 5,013,786 C-shares as of 15 August 2025, which corresponds to 2.79% of the outstanding capital. The total number of shares in Truecaller, including own shares, now amounts to 353,750,053 and the number of outstanding shares, excluding own shares, amounts to 343,865,935. For more information, please contact:Andreas Frid, Head of IR & Communication+46 705 29 08 00 About Truecaller: Truecaller (TRUE B) is the leading global platform for verifying contacts and blocking unwanted communication. We enable safe and relevant conversations between people and make it efficient for businesses to connect with consumers. Fraud and unwanted communication are endemic to digital economies. especially in emerging markets. We are on a mission to build trust in communication. Truecaller is an essential part of everyday communication for more than 450 million active users. Truecaller is listed on Nasdaq Stockholm since 8 October 2021. For more information please visit This information was brought to you by Cision The following files are available for download: Press release buybacks week 33 2025 Truecaller 250818 View original content: SOURCE Truecaller AB Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
